How Does Liver Cancer Develop? Causes and Treatment Pathways as of 2026

Liver cancer is a cancer that most often arises on top of long-standing liver damage—chronic hepatitis or cirrhosis. That's why treatment decisions are guided not just by the size of the tumor, but also by whether the liver has enough remaining function to withstand treatment.

Key Takeaways

• Liver cancer usually develops on top of chronic hepatitis or cirrhosis, so both the cancer's stage and the liver's functional grade (Child-Pugh) together determine treatment, along with portal pressure.
• In Korea, the 5-year relative survival rate for people diagnosed with liver cancer between 2019 and 2023 is 40.4% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea).
• For the same period, the U.S. SEER statistics show a 5-year relative survival rate of 21.9% for liver and intrahepatic bile duct cancer (SEER 2016–2022). Both figures are nationwide statistics, not results from any specific hospital.
• Korea's national screening program, which offers ultrasound and blood tests every six months for people with hepatitis B or cirrhosis, is considered a key factor in detecting cancers at a smaller size.
• In many cases, diagnosis is made based solely on the characteristic blood-flow pattern seen on contrast-enhanced CT or MRI, without a tissue biopsy.

Specifically, how does liver cancer develop?

• Liver cancer usually does not arise suddenly in a healthy liver; rather, it develops on top of a liver that has repeatedly undergone damage and regeneration over a long period, as seen in chronic hepatitis or cirrhosis. For this reason, diagnosing liver cancer involves evaluating not just the tumor itself but also the overall condition of the liver in which the tumor sits.
• In actual diagnostic practice, if a person with cirrhosis or chronic hepatitis undergoes contrast-enhanced CT or MRI and shows the characteristic blood-flow pattern—strong enhancement of the tumor in the arterial phase followed by washout—this pattern alone is sufficient to diagnose liver cancer. Tumor marker levels such as AFP are considered alongside this, and a biopsy is added only when imaging findings are ambiguous or when metastasis from another cancer to the liver is suspected.
• Three things are always assessed together when evaluating liver cancer: the number, size, and vascular invasion of tumors; the liver function grade (Child-Pugh), which combines bilirubin, albumin, and coagulation levels along with the presence of ascites and jaundice; and the patient's overall physical condition. Because of this, treatment for liver cancer is not decided by TNM staging alone, and staging systems that combine all three factors (such as BCLC) are widely used.

How does treatment differ by stage? (in order)

• Stage 1: Very early/early stage — If the tumor is small, few in number, and liver function is good, liver resection (surgical removal) is the first choice. When the tumor's location allows, laparoscopic or robotic resection is used to speed recovery; if resection is not feasible, radiofrequency ablation is used to burn away the tumor. If liver function is significantly reduced but the tumor size and number fall within established criteria, liver transplantation becomes the definitive treatment.
• Stage 2: Intermediate stage — When multiple tumors are present within the liver, transarterial chemoembolization (TACE), which blocks the blood vessels feeding the tumors, is the central approach, and radioembolization is also used in some cases. Combining stereotactic radiotherapy (SBRT) with particle therapy, or prioritizing systemic drug therapy, is also considered depending on the situation.
• Stage 3: Advanced stage — When there is vascular invasion or spread outside the liver, systemic drug therapy becomes central. A combination of immune checkpoint inhibitors and angiogenesis inhibitors is now part of the standard first-line treatment, and oral targeted therapies are used depending on the patient's condition.
• Stage 4: Severely impaired liver function — Since chemotherapy can further damage the liver in this state, the focus shifts to symptom control, preserving remaining liver function, and evaluating the possibility of transplantation.

Why does liver cancer require such frequent follow-up?

• Liver cancer can recur as a new tumor elsewhere in the liver, separate from the originally treated site, so follow-up intervals tend to be tighter than for other cancers. Typically, for the first one to two years after treatment, contrast-enhanced CT or MRI along with AFP testing is repeated every few months, with the interval gradually lengthened afterward.
• People with chronic hepatitis B or C need to continue antiviral treatment and liver function tests for life. This is to consistently manage the underlying liver disease that gives rise to liver cancer in the first place.
• Survival rates are population averages and do not predict any individual's outcome. Even with tumors of the same size and number, the recommended treatment can differ completely depending on liver function, portal pressure, and hepatitis status.

FAQ — Do I need to keep taking hepatitis B medication?

Yes. It is standard practice to continue antiviral medication without interruption before, during, and after liver cancer treatment. Since liver cancer arises on the foundation of hepatitis or cirrhosis, controlling the virus is a key factor in protecting liver function alongside cancer treatment.

FAQ — Whose results do the survival statistics represent?

These are nationwide statistics for all of Korea, not figures from any specific hospital (National Cancer Registration Statistics 2019–2023). Under Korean medical law, hospital-specific outcomes may not be used in advertising, and actual treatment results can vary from person to person depending on stage and liver function.

Sources and Notes

• This article was written with reference to the National Cancer Registration Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center Korea), SEER 2016–2022 (U.S. National Cancer Institute), the National Cancer Information Center, and NCCN patient guidelines.
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult with your medical team to determine an accurate diagnosis and treatment plan.